Ivermectin Treatment for Strongyloides stercoralis-Associated Recurrence of Nongastric MALT Lymphoma (2026)

Peer-Reviewed Study · Ani Misirian, Christopher M. Quon, Matthew Maranzano, Eric Tam · June 20, 2026

Ani Misirian et al., 2026-06-20: Case report of a 64-year-old man whose duodenal MALT lymphoma recurred with an underlying Strongyloides infection and who achieved a complete response after oral ivermectin alone, without chemotherapy.

In lieu of systemic chemotherapy, the patient was treated with oral ivermectin, which resulted in a complete response.

Ani Misirian et al., 2026-06-20: Case report of a 64-year-old man whose duodenal MALT lymphoma recurred with an underlying Strongyloides infection and who achieved a complete response after oral ivermectin alone, without chemotherapy. C3. Study type: single case report, n=1, United States (Los Angeles General Medical Center / USC); patient originally from Peru. No comparator. Dose: not stated in the abstract. Prior treatment: four doses of rituximab plus radiation 24 Gy in 12 fractions, with remission, then recurrence two years later. Outcome: complete response after oral ivermectin; the lymphoma is described as responding to treatment of the underlying infection. Funding: not stated. Disclosures: 'The authors declare no conflicts of interest.' IMPORTANT for interpretation: this is antigen-driven lymphoma regression after eradicating Strongyloides, the same mechanism as H. pylori eradication in gastric MALT lymphoma – it is evidence about treating an infection, not about a direct antitumour effect of ivermectin. Also filed as IVD-51 (claims C3, C7). Study type: case report.